Ambrx, Inc.
http://www.ambryxbio.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ambrx, Inc.
Five Recent Deals Show ADCs Aren’t Cooling Off For Summer
While 2024 has seen two buyouts of antibody-drug conjugate specialists with $1bn-plus price tags, the focus on ADCs has continued, accounting for almost half of recent oncology deals.
M&A Activity During Q2 Declined In Volume And Valuation
Following a pair of $10bn+ deals in Q4 2023 and a $16.5bn takeout in Q1, the second quarter saw no acquisition priced as high as $5bn, Evaluate notes. Aggregate deal volume and values dropped from Q1.
Biopharma Market’s Green Shoots Are Evident But Full Recovery Must Wait Awhile
Biopharma markets may follow the downward trajectory of tech during tough times, but they also chase it back up the value curve. Recovery is just a matter of time, says Seventure’s Isabelle de Crémoux in this commentary on investment trends, the financial markets and the VC environment.
BIO Notebook: FDA User Fees For AI Regulation, Partnering Strategy Evolves, And More
Insights from Day Two of the BIO International Convention in San Diego include the evolving pros and cons of partnering, user fees potentially supporting the FDA's AI ambitions, and J&J's view on dealmaking in 2024.
Company Information
- Industry
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice